tiprankstipranks
Biogen Inc. (BIIB)
NASDAQ:BIIB
US Market
BIIB
Biogen
RESEARCH TOOLSreports
Want to see BIIB full AI Analyst Report?

Biogen (BIIB) Stock Forecast & Price Target

5,057 Followers
See the Price Targets and Ratings of:

BIIB Analyst Ratings

Moderate Buy
28Ratings
Moderate Buy
18 Buy
9 Hold
1 Sell
Based on 28 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$233.29
▲(15.38% Upside)
Based on 28 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $233.29 with a high forecast of $300.00 and a low forecast of $157.00. The average price target represents a 15.38% change from the last price of $202.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"130":"$130","301":"$301","172.75":"$172.8","215.5":"$215.5","258.25":"$258.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":233.29166666666669,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$233.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$157.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[130,172.75,215.5,258.25,301],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,202.95,210.4153846153846,217.88076923076923,225.34615384615384,232.81153846153845,240.27692307692308,247.7423076923077,255.2076923076923,262.6730769230769,270.13846153846157,277.6038461538461,285.0692307692308,292.5346153846154,{"y":300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,202.95,205.28397435897435,207.6179487179487,209.95192307692307,212.28589743589743,214.61987179487178,216.95384615384614,219.28782051282053,221.6217948717949,223.95576923076925,226.2897435897436,228.62371794871797,230.95769230769233,{"y":233.29166666666669,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,202.95,199.4153846153846,195.88076923076923,192.34615384615384,188.81153846153845,185.27692307692308,181.7423076923077,178.2076923076923,174.6730769230769,171.13846153846154,167.60384615384615,164.06923076923078,160.5346153846154,{"y":157,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.23,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.74,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.95,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$300.00Average Price Target$233.29Lowest Price Target$157.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$200→$215
Hold
6.34%
Upside
Reiterated
08/03/26
Biogen price target raised to $215 from $200 at CitiBiogen price target raised to $215 from $200 at Citi
Mizuho Securities Analyst forecast on BIIB
Salim Syed
Mizuho Securities
Mizuho Securities
$221→$241
Buy
19.19%
Upside
Reiterated
08/03/26
Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$214→$242
Buy
19.69%
Upside
Reiterated
08/02/26
Stifel Nicolaus Remains a Buy on Biogen (BIIB)
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$215
Hold
6.34%
Upside
Assigned
07/31/26
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Truist Financial Analyst forecast on BIIB
Danielle Brill
Truist Financial
Truist Financial
$235
Buy
16.23%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Xencor (NASDAQ: XNCR)
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$237→$251
Buy
24.14%
Upside
Reiterated
07/30/26
Biogen price target raised to $251 from $237 at H.C. WainwrightBiogen price target raised to $251 from $237 at H.C. Wainwright
Jefferies Analyst forecast on BIIB
Andrew Tsai
Jefferies
Jefferies
$255
Buy
26.12%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), Teladoc (NYSE: TDOC) and Damora Therapeutics (NASDAQ: DMRA)
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
23.65%
Upside
Reiterated
07/30/26
Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$222→$231
Hold
14.25%
Upside
Reiterated
07/30/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$245→$248
Buy
22.66%
Upside
Reiterated
07/30/26
Biogen price target raised to $248 from $245 at CanaccordBiogen price target raised to $248 from $245 at Canaccord
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$196→$208
Hold
2.87%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Fortrea Holdings Inc. (NASDAQ: FTRE)
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215→$225
Buy
11.28%
Upside
Assigned
07/30/26
Analysts' Top Healthcare Picks: Icon (ICLR), Biogen (BIIB)
J.P. Morgan Analyst forecast on BIIB
Chris Schott
J.P. Morgan
J.P. Morgan
$185→$210
Hold
3.86%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN), Biogen (NASDAQ: BIIB) and Doximity (NYSE: DOCS)
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$225→$240
Buy
18.70%
Upside
Reiterated
07/30/26
Analysts' Top Healthcare Picks: Pulmonx (LUNG), Ocugen (OCGN)
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
$256
Buy
26.61%
Upside
Reiterated
07/29/26
Biogen: Buy Rating Reiterated on Strong Q2 Beat and Upgraded 2026 Outlook; Price Target Maintained at $256
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$200→$215
Hold
6.34%
Upside
Reiterated
08/03/26
Biogen price target raised to $215 from $200 at CitiBiogen price target raised to $215 from $200 at Citi
Mizuho Securities Analyst forecast on BIIB
Salim Syed
Mizuho Securities
Mizuho Securities
$221→$241
Buy
19.19%
Upside
Reiterated
08/03/26
Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$214→$242
Buy
19.69%
Upside
Reiterated
08/02/26
Stifel Nicolaus Remains a Buy on Biogen (BIIB)
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$215
Hold
6.34%
Upside
Assigned
07/31/26
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Truist Financial Analyst forecast on BIIB
Danielle Brill
Truist Financial
Truist Financial
$235
Buy
16.23%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Xencor (NASDAQ: XNCR)
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$237→$251
Buy
24.14%
Upside
Reiterated
07/30/26
Biogen price target raised to $251 from $237 at H.C. WainwrightBiogen price target raised to $251 from $237 at H.C. Wainwright
Jefferies Analyst forecast on BIIB
Andrew Tsai
Jefferies
Jefferies
$255
Buy
26.12%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), Teladoc (NYSE: TDOC) and Damora Therapeutics (NASDAQ: DMRA)
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
23.65%
Upside
Reiterated
07/30/26
Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$222→$231
Hold
14.25%
Upside
Reiterated
07/30/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$245→$248
Buy
22.66%
Upside
Reiterated
07/30/26
Biogen price target raised to $248 from $245 at CanaccordBiogen price target raised to $248 from $245 at Canaccord
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$196→$208
Hold
2.87%
Upside
Reiterated
07/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Fortrea Holdings Inc. (NASDAQ: FTRE)
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215→$225
Buy
11.28%
Upside
Assigned
07/30/26
Analysts' Top Healthcare Picks: Icon (ICLR), Biogen (BIIB)
J.P. Morgan Analyst forecast on BIIB
Chris Schott
J.P. Morgan
J.P. Morgan
$185→$210
Hold
3.86%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN), Biogen (NASDAQ: BIIB) and Doximity (NYSE: DOCS)
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$225→$240
Buy
18.70%
Upside
Reiterated
07/30/26
Analysts' Top Healthcare Picks: Pulmonx (LUNG), Ocugen (OCGN)
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
$256
Buy
26.61%
Upside
Reiterated
07/29/26
Biogen: Buy Rating Reiterated on Strong Q2 Beat and Upgraded 2026 Outlook; Price Target Maintained at $256
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months
Myles MinterWilliam Blair
Success Rate
13/23 ratings generated profit
57%
Average Return
+1.89%
Copying Myles Minter's trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +1.89% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
16/23 ratings generated profit
70%
Average Return
+13.77%
Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +13.77% per trade.
2 Years
Myles MinterWilliam Blair
Success Rate
15/23 ratings generated profit
65%
Average Return
+7.99%
Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +7.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
31
39
41
54
38
Hold
40
39
32
34
21
Sell
1
1
0
1
1
Strong Sell
0
0
0
0
0
total
72
79
73
89
60
In the current month, BIIB has received 38 Buy Ratings, 21 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the past 3 months is 233.29.
Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $2.09 with a range of $1.44 to $3.53. The previous quarter’s EPS was $3.60. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.38% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s earnings estimate for BIIB is $2.09 with a range of $1.44 to $3.53. The previous quarter’s EPS was $3.60. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.38% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.63B with a range of $2.50B to $2.73B. The previous quarter’s sales results were $2.62B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 29.50% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s sales forecast for BIIB is $2.63B with a range of $2.50B to $2.73B. The previous quarter’s sales results were $2.62B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 29.50% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen Inc.’s 12-month average price target is 233.29.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Biogen Inc. has 15.38% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIIB a Buy, Sell or Hold?
          Biogen Inc. has a consensus rating of Moderate Buy which is based on 18 buy ratings, 9 hold ratings and 1 sell ratings.
            What is Biogen Inc.’s price target?
            The average price target for Biogen Inc. is 233.29. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $300.00 ,the lowest forecast is $157.00. The average price target represents 15.38% Increase from the current price of $202.19.
              What do analysts say about Biogen Inc.?
              Biogen Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 28 Wall Streets Analysts.
                How can I buy shares of BIIB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.